Ignite Creation Date:
2024-05-06 @ 7:43 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02588443
Status:
COMPLETED
Last Update Posted:
2022-09-06
First Post:
2015-10-21
Brief Title:
Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Organization Data
Organization:
Abramson Cancer Center at Penn Medicine
Class:
OTHER
Study ID:
UPCC 20214
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None